Articles

Fasting glucose levels may independently predict the risk of being hospitalized with congestive heart failure in heart attack survivors and others who are at high risk of developing the disorder.

A new study suggests that participation in the Chinese martial art Tai Chi Chuan may help boost immune function and improve blood sugar control in people with type 2 diabetes.

Pioglitazone significantly reduces the risk of first-time stroke and recurrent stroke in high-risk patients with type 2 diabetes, a European group reports.

The change which started last Sat evening for the beginning and end of daylight saving time (DST) may adversely affect medical equipment that uses date and time information for diagnosis or treatment. The new DST will begin 3 weeks earlier and end one week later this year.

Researchers have developed a simple breath test for detecting Type 1 diabetes, and say that the new non-invasive tool could possibly be an economical method for tracking day-to-day glucose levels.

The German Diabetes Risk Score which is based on anthropometric, dietary, and lifestyle factors, was an effective tool to identify patients at high risk or with undiagnosed diabetes, according to the results of a study. 

The FDA has approved aliskiren (Tektuma), the first oral direct renin inhibitor for treatment of hypertension. The drug is the first in a new class of agents known as oral renin inhibitors and is approved for the treatment of high blood pressure as monotherapy or in combination with other antihypertensive …

Researchers with Deakin’s Center for Physical Activity and Nutrition Research surveyed more than 1200 families to find out if parents had concerns about their children’s weight and if they took any preventative action to avoid obesity in their children.

Those who consumed one or more soft drinks per day were twice as likely as those who consumed less than one per month to develop diabetes

Te FDA approved safety labeling revisions for the antidiabetic agents pioglitazone and pioglitazone/metformin to warn of interactions associated with concomitant use of the pioglitazone component and drugs known to induce or inhibit the cytochrome P (CYP) 450 isoenzyme 2C8 (CYP 2C8).